Mike Kratky
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
28
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $70.35 | +23.67% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $190.71 | +3.30% | 2 | Sep 10, 2024 | |
| TXG 10x Genomics | Initiates: Outperform | $35 | $16.33 | +114.33% | 1 | Sep 3, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $233.30 | +12.73% | 1 | Sep 3, 2024 | |
| NARI Inari Medical | Initiates: Market Perform | $47 | $48.74 | -3.57% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $31.91 | +41.02% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $6.29 | +249.76% | 1 | Jan 30, 2024 | |
| AXNX Axonics | Downgrades: Market Perform | $71 | $70.37 | +0.90% | 2 | Jan 12, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $235.61 | -21.90% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $43.99 | -4.52% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $506.34 | -32.46% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $67.54 | +11.05% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $92.29 | -59.91% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $13.95 | -35.48% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $6.75 | +640.74% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $14.52 | +209.92% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $319.58 | -1.43% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $46.47 | -33.29% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $29.39 | -52.36% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $22.28 | +79.53% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $2.23 | +2,052.47% | 1 | Aug 11, 2022 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $70.35
Upside: +23.67%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $190.71
Upside: +3.30%
10x Genomics
Sep 3, 2024
Initiates: Outperform
Price Target: $35
Current: $16.33
Upside: +114.33%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $233.30
Upside: +12.73%
Inari Medical
Sep 3, 2024
Initiates: Market Perform
Price Target: $47
Current: $48.74
Upside: -3.57%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $31.91
Upside: +41.02%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $6.29
Upside: +249.76%
Axonics
Jan 12, 2024
Downgrades: Market Perform
Price Target: $71
Current: $70.37
Upside: +0.90%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $235.61
Upside: -21.90%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $43.99
Upside: -4.52%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $506.34
Upside: -32.46%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $67.54
Upside: +11.05%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $92.29
Upside: -59.91%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $13.95
Upside: -35.48%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $6.75
Upside: +640.74%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $14.52
Upside: +209.92%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $319.58
Upside: -1.43%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $46.47
Upside: -33.29%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $29.39
Upside: -52.36%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $22.28
Upside: +79.53%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $2.23
Upside: +2,052.47%